Helus Pharma (NASDAQ: HELP; Cboe CA: HELP), a clinical-stage pharmaceutical company focused on developing novel serotonergic agonists for mental health disorders, announced the appointment of Michael Cola as Chief Executive Officer, effective immediately. The leadership change comes as the company advances its pipeline toward key clinical and corporate milestones, including expected Phase 2 data for HLP004 this quarter and Phase 3 topline data for HLP003 in Q4 2026. Cola, who brings extensive experience in the biopharmaceutical industry, will oversee the company's transition toward later-stage development, regulatory engagement, and long-term commercial planning.
Helus Pharma is currently developing HLP003, a proprietary novel serotonergic agonist (NSA) in Phase 3 clinical development for the adjunctive treatment of major depressive disorder, which has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration. The company is also advancing HLP004, another proprietary NSA in Phase 2 for generalized anxiety disorder. Additionally, Helus Pharma has an extensive research portfolio of investigational NSAs designed to activate serotonin pathways believed to promote neuroplasticity.
The appointment of Cola signals a strategic shift as the company moves beyond early-stage research and into late-stage clinical development and commercialization planning. According to the press release, the company is continuing to expand a broad global intellectual property portfolio. The full announcement can be accessed at https://ibn.fm/VugQZ.
Helus Pharma, the commercial operating name of Cybin Inc., was founded in 2019 and operates in Canada, the United States, the United Kingdom, and Ireland. The company aims to address the large unmet need for people who suffer from depression, anxiety, and other mental health conditions by developing synthetic molecules designed to provide durable improvements in mental health. For more information about Helus Pharma, visit www.helus.com.
The announcement was disseminated by BioMedWire, a specialized communications platform focusing on biotechnology and life sciences. The latest news and updates regarding HELP are available at https://ibn.fm/HELP.
